Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

March 26, 2019 Fred Dumais

LAVAL, QUEBEC, CANADA – March 26, 2019 – Prometic Life Sciences Inc. (TSX:
PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it will
report its financial results for the fourth quarter and year ended December 31, 2018 on
Monday April 1, 2019 after market close.

Prometic will host a conference call at 11:00am (ET) on Tuesday April 2, 2019. The
telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450.
An audio replay of the call will be available as of Tuesday April 2, 2019 at 2:00pm (ET).
The numbers to access the audio replay are 416-849-0833 and 1-855-859-2056 using
the following password (3198209).

A live audio webcast of the conference call will be available via:
https://event.on24.com/wcc/r/1969851/0D5A0C85F48EBF7260AFC1BE9877F748


About Prometic Life Sciences Inc.

Prometic (www.prometic.com) is a biopharmaceutical corporation with two drug discovery
platforms focusing on unmet medical needs. The first platform (small molecule
therapeutics) stems from the discovery of two receptors which we believe are at the core
of how the body heals: namely, promoting tissue regeneration and scar resolution as
opposed to fibrosis. One of the lead drug candidates emerging from this platform, PBI-
4050, is expected to enter pivotal phase 3 clinical trials for the treatment of Alström
syndrome. The second drug discovery and development platform (plasma-derived
therapeutics) leverages Prometic’s experience in bioseparation technologies used to
isolate and purify biopharmaceuticals from human plasma. The Corporation’s primary
goal with respect to this second platform is to address unmet medical needs with
therapeutic proteins not currently commercially available, such as Ryplazim™
(plasminogen). We are also leveraging this platform’s higher recovery yield potential to
advance novel and established plasma-derived therapeutics. The Corporation also
provides access to its proprietary bioseparation technologies to enable pharmaceutical
companies in their production of non-competing biopharmaceuticals. Recognized as a bioseparations expert, the Corporation derives revenue from this activity through sales of
affinity chromatography media which contributes to offset the costs of its own R&D
investments.

We are headquartered in Laval, Quebec (Canada) and have R&D facilities in Canada,
the United Kingdom (“UK”) and the United States (“USA”), manufacturing facilities in
Canada and the Isle of Man and corporate and business development activities in
Canada, the USA, Europe and Asia.

Forward Looking Statements
This press release contains forward-looking statements about Prometic’s objectives,
strategies and businesses that involve risks and uncertainties. These statements are
“forward-looking” because they are based on our current expectations about the markets
we operate in and on various estimates and assumptions. Actual events or results may
differ materially from those anticipated in these forward-looking statements if known or
unknown risks affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to, Prometic’s ability
to develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic to take advantage of
business opportunities in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to materially
differ from our current expectations in Prometic’s Annual Information Form for the year
ended December 31, 2017, under the heading “Risk and Uncertainties related to
Prometic’s business”. As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of future events or for
any other reason, unless required by applicable securities laws and regulations. All
amounts are in Canadian dollars unless indicated otherwise.

For further information please contact:

Corporate Contacts:
Simon Best
Chairman and interim CEO
Prometic Life Sciences Inc.
s.best@prometic.com
450.781.0115

Frederic Dumais
Senior Director, Communications & Investor Relations
Prometic Life Sciences Inc.
f.dumais@prometic.com
450-781-0115

About the Author

Fred Dumais

Fred is responsible for leading Prometic’s investor relations team and is accountable for all global investor relations activity, PR and event management. He joined the company in 2001, and brings nearly twenty years of experience in investor and financial communications, as well as a deep experience of the pharmaceutical industry. He has extensive knowledge of the global financial markets in the US, Europe and his native country of Canada. Fred is a graduate from Concordia University where he gained a BA in Business Communications. He also brings to the role a background in law with a LLB from the University of Québec.

Follow on Linkedin More Content by Fred Dumais
Previous Article
Prometic reports fourth quarter and 2018 year-end financial results
Prometic reports fourth quarter and 2018 year-end financial results

Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in biosepa...

Next Article
Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP
Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP